Previous 10 | Next 10 |
home / stock / mmed:cc / mmed:cc news
MindMed Announces Pricing of Public Offering of Common Shares and Warrants Canada NewsWire NEW YORK , Sept. 27, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. ("MindMed") (NASDAQ: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel ...
MindMed Announces Proposed Public Offering of Common Shares Canada NewsWire NEW YORK , Sept. 27, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. ("MindMed") (Nasdaq: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel products t...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 22, 2022 – Atlanta just became the latest city to consider decriminalizing psychedelics. On September 12, just one week after San Francisco officially decriminali...
MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances Canada NewsWire First-in-human trial to investigate the tolerability, pharmacology, and pharmacokinetics of novel MDMA-like compounds versus a placebo in heal...
MindMed Announces Compliance with Nasdaq Listing Requirements Canada NewsWire NEW YORK , Sept. 14, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing ...
MindMed Announces Positive Results from Collaborators' Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal Canada NewsWire - Data from University Hospital Basel (UHB) study supports the clinical development of MindMed's proprietary MM-120...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 7, 2022 – According to a new survey by Johns Hopkins Medicine researchers, people’s attitudes toward death change after a psychedelic drug experience and a non-d...
MindMed to Participate in H.C. Wainwright Global Investment Conference Canada NewsWire NEW YORK , Sept. 7, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company dev...
MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder Canada NewsWire NEW YORK , Aug. 25, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage...
IIROC Trade Resumption - MMED Canada NewsWire TORONTO , Aug. 23, 2022 /CNW/ - Trading resumes in: Company: MIND MEDICINE (MINDMED) INC. NEO Exchange Symbol: MMED All Issues: No Resumption (ET): 9:39:10 AM IIROC can make a decision to i...
News, Short Squeeze, Breakout and More Instantly...
Hallucinogenic persistent perception disorder (HPPD) is an intoxication disorder caused by psychedelic drugs that encompasses a range of visual disturbances that occur in different time frames. The disorder also causes extreme anxiety as well as out-of-body sensations and is marked by shame as w...
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the...
All Common shares will remain listed on Nasdaq Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today ...